Q3:16 Health Care M&A Results: Context Is Everything
Brace yourself. The third quarter results for health care mergers and acquisitions signal a hard tap on the brakes, both in deal volume and value. That’s compared with the robust second quarter, and the same quarter a year ago. Before we go any further, though, we must note that, compared with all previous third quarters stretching back to 2000, the third quarter of 2016 doesn’t look that bad. Some 369 transactions are now on the books for Q3:16, which ranks this quarter as the second-highest in deal volume for any previous third quarter. The top-ranked third quarter, coincidently, came a year ago, when Q3:15 racked up 411 transactions. So Q3:16’s deal volume slid 10% compared with the... Read More »LabCorp Ventures into Prenatal Testing
LabCorp (NYSE: LH), the world’s leading healthcare diagnostics company, has acquired Sequenom Inc. (NASDAQ: SQNM), a pioneer in non-invasive prenatal testing (NIPT) for reproductive health, for a total purchase price of $371 million. In July of 2014, Sequenom purchased a license for non-invasive prenatal testing patents and applications from privately-held Mayo Medical Laboratories, and two months later it acquired intellectual property from privately-held Isis Innovation for non-invasive prenatal testing intellectual property. Today, Sequenom is the first laboratory to offer a clinically validated NIPT test (MaterniT®21), which has completed more than 500,000 tests to date. LabCorp’s most... Read More »June 2016 M&A Results Show Strength
Uncertainty is the hobgoblin of the merger and acquisition markets, and the month of June was a high point (or low point, depending on your perspective) for anxiety in global financial markets. Still, the healthcare deals kept rolling in. Our preliminary total for June 2016 stands at 115 transactions, exactly equal with the same month a year ago. Compared with May’s total of 141 deals, though, June’s total does look as if someone is applying the brakes. It takes 12 months to make a year, though, and one month’s results do not create a trend. The digital health sector turned in the strongest gain compared with June 2015, when only two deals were announced. This June, 22 deals were announced... Read More »Schryver Nabs Another Lab
If it’s true that 70% or more of medical decisions are made based on diagnostic testing results, then one can assume that the Laboratory, MRI & Dialysis sector is at the crossroads where fee-for-service and value-based reimbursements meet. Although this sector isn’t the largest in transaction volume and dollars spent relative to other markets, mergers and acquisition activity has picked up in 2016, as these lines of business adjust to changes in technology. Since 2014, there have been 104 acquisitions, and $21.8 billion (of disclosed prices) spent in the Laboratory, MRI & Dialysis sector (33 in 2014; 52 in 2015; and 19 as of June 30, 2016). The largest players buying up laboratory... Read More »Quintiles/IMS Merger Keeps Lab Sector Humming
Laboratories are big business, and they’re trading for very strong multiples these days. This year in particular, we’ve seen a lot of global M&A action around contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). The most recent announcement was the all-stock merger of equals between Quintiles (NYSE: Q) and IMS Health Holdings (NYSE: IMS). First, the details. IMS Health shareholders will receive a fixed exchange ratio of 0.384 shares of Quintiles common stock for each share of IMS Health common stock. Upon completion, IMS shareholders will own approximately 51.4% of the shares of the combined company on a fully diluted... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
